Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ain Shams University
1- To evaluate the effect of sildenafil on pulmonary artery pressure and right ventricular function in hemodialysis patients with pulmonary hypertension.
1. Primary outcome:
● Reduction in estimated Pulmonary Artery pressure value (ePAP) in mmHg via transthoracic Doppler Echocardiography.
2. Secondary outcomes:
* Detection of safety of sildenafil in hemodialysis patients.
* Finding out sildenafil's optimum dose for hemodialysis patients with pulmonary hypertension.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age from 18-80 years old.
2. Patients on maintenance hemodialysis for more than six months receiving 3 sessions / week using bicarbonate dialysate with a low flux filter and heparin as anticoagulant.
5-Human immunodeficiency virus (HIV) infection. 6-History of hypersensitivity to sildenafil. 7-Treatment with any drugs that may interact with sildenafil (Erythromycin , Azoles, Saquinavir-CYP3A4 inhibitors- , Bosentan - CYP3A4 inducer-Nitrates ) 8- Uncontrolled hypertension 9- Anemia with hemoglobin level \<10 g/dl
Clareo Health | Sildenafil in Hemodialysis Patients With Pulmonary Hypertension
